Look through the key statistics analysis before diving in deeper into our report:
| Parameter | Current result | Assessment |
|---|---|---|
| Meta title | Genentech® Transplant Access Services | GTAS | As meta title is a ranking factor, it's quite important to stick to search engine recommended length of aroun 50-60 characters. This website's meta title is 44 characters long. |
| Description | Connect your transplant patients with Valcyte® (valganciclovir hydrochloride) & CellCept® (mycophenolate mofetil) patient assistance & reimbursement services. Valcyte – Indication and Important Safety Information INDICATIONS: Adult Patients: Valcyte® (valganciclovir hydrochloride) is indicated for the treatment of cytomegalovirus (CMV) disease in kidney, heart, and kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]). Pediatric Patients: Valcyte is indicated for the prevention of CMV disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk. Adult patients should use Valcyte tablets, not Valcyte for oral solution. Valcyte for oral solution (50 mg/mL) must be prepared by the pharmacist prior to dispensing to the patient. IMPORTANT SAFETY INFORMATION - WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS • Hematologic Toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow failure, and aplastic anemia have been reported in patients treated with Valcyte • Impairment of Fertility: Based on animal data, Valcyte may cause temporary or permanent inhibition of spermatogenesis • Fetal Toxicity: Based on animal data, Valcyte has the potential to cause birth defects in humans • Mutagenesis and Carcinogenesis: Based on animal data, Valcyte has the potential to cause cancers in humans CONTRAINDICATION Valcyte is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (eg, anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation. WARNINGS AND PRECAUTIONS: • Hematologic toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, and aplastic anemia have occurred with the use of Valcyte or ganciclovir. Avoid Valcyte use if absolute neutrophil count is less than 500 cells/μL, platelet count is less than 25,000/μL, or hemoglobin is less than 8 g/dL. Use with caution in pre-existing cytopenias and when receiving myelosuppressive drugs or irradiation. Monitor with frequent testing of platelet and complete blood counts. In patients with severe leukopenia, neutropenia, anemia and/or thrombocytopenia, treatment with hematopoietic growth factors and or the interruption of therapy is recommended. Patients with low baseline platelet counts (<100,000 /μL) have an increased risk of developing thrombocytopenia. Patients with iatrogenic immunosuppression due to treatment with immunosuppressive drugs are at greater risk of thrombocytopenia than patients with AIDS. Severe thrombocytopenia may be associated with potentially life-threatening bleeding. • Impairment of fertility: Based on animal studies, Valcyte may cause temporary or permanent inhibition of spermatogenesis. Advise patients that fertility may be impaired with use of Valcyte. • Fetal toxicity: Based on animal studies, Valcyte may cause fetal harm. Pregnancy should be avoided in female patients taking Valcyte and in females with male partners taking Valcyte. Females of reproductive potential should be advised of the potential risk to the fetus and use effective contraception during and following treatment and males should practice barrier contraception during and following treatment. • Mutagenicity and carcinogenicity: Based on animal studies, Valcyte is potentially mutagenic and carcinogenic. • Acute renal failure: Acute renal failure may occur in elderly patients (with or without reduced renal function), patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients. Use with caution in elderly patients or those taking nephrotoxic drugs, reduce dosage in patients with renal impairment, and monitor renal function. Adequate hydration should be maintained for all patients. • Cross hypersensitivity: Due to the similarity of the chemical structure of ganciclovir and that of aciclovir and valaciclovir, a cross-hypersensitivity reaction between these drugs is possible. Caution should therefore be used when prescribing Valcyte to patients with known hypersensitivity to aciclovir or penciclovir, or to their prodrugs, valaciclovir or famciclovir. • Potential drug interactions: Toxicity may be enhanced when Valcyte is co-administered with other drugs known to be myelosuppressive or associated with renal impairment. These drugs should only be considered for concomitant use with valganciclovir if the potential benefits outweigh the potential risks. ◦ Zidovudine: Potential to cause neutropenia and anemia. Monitor with frequent tests of white blood cell counts with differential and hemoglobin levels. ◦ Probenecid: May increase ganciclovir levels. Monitor for evidence of ganciclovir toxicity. ◦ Mycophenolate mofetil (MMF): Based on increased risk, patients should be monitored for hematological and renal toxicity. ◦ Didanosine: May increase didanosine concentrations. Monitor for didanosine toxicity (eg, pancreatitis). ADVERSE REACTIONS Adult Patients: The most common adverse reactions and laboratory abnormalities reported in at least one indication by ≥20% of adult patients are diarrhea, pyrexia, nausea, tremor, neutropenia, anemia, graft rejection, thrombocytopenia, and vomiting. Pediatric Patients: The most common adverse reactions and laboratory abnormalities reported in ≥20% of pediatric solid organ transplant recipients are diarrhea, pyrexia, hypertension, upper respiratory tract infection, urinary tract infection, vomiting, neutropenia, leukopenia, and headache. Please see accompanying full Prescribing Information, including Boxed WARNINGS, for additional important safety information. CellCept – Indication and Important Safety Information INDICATION: CellCept® (mycophenolate mofetil) is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids. CellCept Intravenous is an alternative dosage form to CellCept capsules, tablets, and oral suspension. CellCept Intravenous should be administered within 24 hours following transplantation. CellCept Intravenous can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication. IMPORTANT SAFETY INFORMATION: WARNING: EMBRYO FETAL TOXICITY, MALIGNANCIES, AND SERIOUS INFECTIONS Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Females of reproductive potential (FRP) must be counseled regarding pregnancy prevention and planning. Immunosuppression may lead to increased susceptibility to infection and possible development of lymphoma. Only physicians experienced in immunosuppressive therapy and management of renal, cardiac, or hepatic transplant patients should prescribe CellCept. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient. CONTRAINDICATIONS: CellCept is contraindicated in patients with a hypersensitivity to mycophenolate mofetil, mycophenolic acid or any component of the drug product. CellCept Intravenous is contraindicated in patients who are allergic to Polysorbate 80 (TWEEN). WARNINGS: • Pregnancy category D: Mycophenolate mofetil (MMF) can cause fetal harm when administered to a pregnant female. Use of MMF during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney, and nervous system. Females of reproductive potential must be made aware of the increased risk of first trimester pregnancy loss and congenital malformations and must be counseled regarding pregnancy prevention and planning. • Patients receiving immunosuppressive regimens involving combinations of drugs, including CellCept, as part of an immunosuppressive regimen are at increased risk of developing lymphomas and other malignancies, particularly of the skin. • CellCept has been administered in combination with the following agents in clinical trials: antithymocyte globulin, OKT3, cyclosporine, and corticosteroids. The efficacy and safety of the use of CellCept in combination with other immunosuppressive agents have not been determined. Because of the danger of oversuppression of the immune system which can increase susceptibility to infection, which may lead to serious, including fatal outcomes, combination immunosuppressant therapy should be used with caution. • Polyomavirus associated nephropathy (PVAN), JC virus associated progressive multifocal leukoencephalopathy (PML), cytomegalovirus (CMV) infections, reactivation of hepatitis B (HBV) or hepatitis C (HCV) have been reported in patients treated with immunosuppressants, including CellCept. Reduction in immunosuppression should be considered for patients who develop evidence of new or reactivated viral infections. Physicians should also consider the risk that reduced immunosuppression represents to the functioning allograft. • Monitor patients for neutropenia. If neutropenia develops [absolute neutrophil count (ANC) <1.3 x 103/μL], dosing with CellCept should be interrupted or the dose reduced, appropriate diagnostic tests performed and the patient managed appropriately. • Cases of pure red cell aplasia (PRCA) have been reported in patients treated with CellCept in combination with other immunosuppressive agents. • CAUTION: CELLCEPT INTRAVENOUS SOLUTION MUST NOT BE ADMINISTERED BY RAPID OR BOLUS INTRAVENOUS INJECTION. PRECAUTIONS: • Females of reproductive potential must be made aware of the increased risk of first trimester pregnancy loss and congenital malformations and must be counseled regarding pregnancy prevention and planning. ◦ Pregnancy Testing: a serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL must be administered immediately before starting CellCept. Another pregnancy test with the same sensitivity should be done 8 to 10 days later. Repeat pregnancy tests should be performed during routine follow-up visits. In the event of a positive pregnancy test, females should be counseled with regard to whether the maternal benefits of mycophenolate treatment may outweigh the risks to the fetus in certain situations, please report the pregnancy to Mycophenolate Pregnancy Registry (1-800-617-8191). ◦ Contraception: Patients taking CellCept must receive contraceptive counseling and use acceptable contraception (see Table 8 of the full Prescribing Information for acceptable contraception methods). Patients must use acceptable birth control during entire CellCept therapy, and for 6 weeks after stopping CellCept, unless the patient chooses abstinence. • CellCept may be used for cardiac or hepatic transplant patients with severe chronic renal impairment if the potential benefits outweigh the potential risks. • A higher incidence of opportunistic infections was observed in cardiac transplant patients treated with CellCept than in those receiving azathioprine therapy. • CellCept should not be administered concomitantly with azathioprine and used with caution when used in the concomitant administration with drugs that interfere with enterohepatic recirculation. • CellCept should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan or Kelley-Seegmiller syndrome. • Gastrointestinal bleeding (requiring hospitalization) has been observed. • During treatment with CellCept, avoid the use of live attenuated vaccines and advise patients that vaccinations may be less effective. • Care should be taken if CellCept Oral Suspension is administered to patients with phenylketonuria. ADVERSE REACTIONS: • The principal adverse reactions associated with the administration of CellCept include diarrhea, leukopenia, sepsis, vomiting, and there is evidence of a higher frequency of certain types of infections, eg, opportunistic infections (see WARNINGS in full Prescribing Information). Phlebitis and thrombosis have been reported with intravenous administration. Please refer to the full Prescribing Information for additional ADVERSE REACTIONS. Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide, for additional Important Safety Information. | This meta description is 12731 characters in length. Google suggests up to 320 characters at the very most to make sure the whole meta description is visible in search results page. |
| Site speed | Around 1.5857 seconds | Website ranking and usability can be greatly improved by reducing the time it takes to load it. |
| Links on homepage | Around 34 links | This is a well-judged amount of links for a homepage. |
| HTML size | 39.3KB | Ah. Well. We were hoping for better results... We would urge the website owners to improve load speed as soon as possible. |
| Website host server overview | Server status: online. Server IP address for this website is 72.34.128.116. | We apologize, but for some reason we were unable to gather enough data to provide a detailed insight at this time. |
If the basic information we presented you with above is not enough, get ready to dive in much deeper!
Servers are physical storage devices that contain all the files and databases associated with a specific website, sometimes more than one. At times, a server makes up several virtual devices - separate servers used for shared hosting (tends to be cheaper). Entering website address into the address bar of your browser starts the request process during which your browser contacts the server and asks for specific files and database entries in order to display the requested website.
What follows is certainly very geeky, but informative for the knowing. Dig in:
| Header detail |
|---|
HTTP/1.1 200 OK Date: Tue, 07 Nov 2017 04:56:23 GMT Content-Disposition: inline;filename="index.html" Accept-Ranges: bytes ETag: /_1509821057516 Last-Modified: Sat, 04 Nov 2017 18:44:17 GMT Content-Range: bytes 0-40042/40042 Content-Length: 40042 Connection: close Content-Type: text/html;charset=UTF-8 Content-Language: en Set-Cookie: BIGipServerws_products_pool=!0/2irYGUS7tCk4XhZrY1cYfRyoiyA3JwtLwrt4bbGI7qEVIoW/nzS5kEMAARLQb1qbuqjr1z78E9QA==; path=/ |
Now that you are hopefully done with transplantaccessservices.com, we invite you to read more of our in-depth reports. Try entering a new domain address in the search form at the top of this page, or on the homepage. Alternatively, refer to this list for more website overviews:
We have found so many alternative TLD extensions for transplantaccessservices.com. Here is the full list with 580 entries:
The following list of most frequent domain address mistypes associated with transplantaccessservices.com contains at least 1353 entries: